SCHEMBL1401339

SCHEMBL1401339

FC(F)(F)c1cccc(C2CCN(CCc3ccc4c(c3)CCNC4)CC2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.55
ASIC3 Q9UHC3 1/20 0.49
HTR2C P28335 2/20 0.48
KDM4A O75164 1/20 0.44
KDM4B O94953 1/20 0.44
KDM5C P41229 1/20 0.44
KDM5B Q9UGL1 1/20 0.44
DRD4 P21917 1/20 0.43
GRM2 Q14416 1/20 0.43
ADRA1D P25100 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
CHRM4 P08173 1/20 0.42
TRPV6 Q9H1D0 1/20 0.42
MCHR1 Q99705 2/20 0.41
KCNH2 Q12809 1/20 0.41
HTR1A P08908 3/20 0.40
HTR2A P28223 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202424 0.96 DRD2 (0.55) DRD2ASIC3HTR2CKDM4AKDM4B
SCHEMBL1401419 0.80 DRD2 (0.60) DRD2HTR2CKDM4AKDM4BKDM5C
Hydrochloric Acid SCHEMBL1401480 0.79 DRD2 (0.58) DRD2HTR2CKDM4AKDM4BKDM5C
SCHEMBL9422688 0.78 DRD2 (0.63) DRD2HTR2CKDM4AKDM4BKDM5C
SCHEMBL9311321 0.78 DRD2 (0.66) DRD2HTR2CKDM4AKDM4BKDM5C
Hydrochloric Acid SCHEMBL9305904 0.77 DRD2 (0.62) DRD2HTR2CKDM4AKDM4BKDM5C
SCHEMBL4587723 0.74 DRD2 (0.57) DRD2HTR2CKDM4AKDM4BKDM5C
SCHEMBL4589239 0.74 DRD2 (0.57) DRD2HTR2CKDM4AKDM4BKDM5C
SCHEMBL1401365 0.73 DRD2 (0.56) DRD2HTR2CKDM4AKDM4BKDM5C
SCHEMBL1401478 0.73 DRD2 (0.56) DRD2HTR2CKDM4AKDM4BKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326720-B2 Phenyl- and pyridylpiperidines with TNF activity SANOFI-AVENTIS (FR) 2008-02-05 US claimed
EP-1383761-B1 Phenyl- and pyridyl-piperidines with tnf activity SANOFI AVENTIS (FR) 2011-03-02 EP disclosed
US-7326720-B2 Phenyl- and pyridylpiperidines with TNF activity SANOFI-AVENTIS (FR) 2008-02-05 US disclosed
US-20040127517-A1 Phenyl-and pyridyl-piperidines with tnf activity SANOFI-AVENTIS (FR) 2004-07-01 US disclosed
EP-1383761-A1 PHENYL- AND PYRIDYL-PIPERIDINES WITH TNF ACTIVITY Sanofi-Aventis (FR) 2004-01-28 EP disclosed
WO-2002085887-A1 PHENYL- AND PYRIDYL-PIPERIDINES WITH TNF ACTIVITY SANOFI-SYNTHELABO (FR) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127517-A1 Phenyl-and pyridyl-piperidines with tnf activity TNF, TNFRSF1A, NGFR DRD2 139/4885ASIC3 2342/4885HTR2C 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.